Investigational medications in the treatment of alopecia

Expert Opinion on Investigational Drugs

Volumn 14, Issue 2, 2005, Pages 177-184

  Poulos, Georgann A ^a   Mirmirani, Paradi ^b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgenetic alopecia; Chemotherapy induced alopecia; Hair loss; Hereditary thinning

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; ANTIANDROGEN; ANTIINFECTIVE AGENT; ANTISENSE OLIGONUCLEOTIDE; APOPTOSIS INHIBITOR; BICALUTAMIDE; BMS 234303; CYPROTERONE ACETATE; ESTERASE INHIBITOR; ESTRONE 3 O SULFAMATE; EUCAPIL; FINASTERIDE; FLURIDIL; FLUTAMIDE; GENISTIN; HYDROXYFLUTAMIDE; KF 19418; KF 19481; LGD 1331; M 50054; MINOXIDIL; NAMINIDIL; NOVOSOME; P 45; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE[7-34]; PHOTOSENSITIZING AGENT; PSK 3841; QLT 0074; RU 58851; SONIC HEDGEHOG PROTEIN; STERYL SULFATASE; THYMOSIN BETA4; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALOPECIA; ANTIINFLAMMATORY ACTIVITY; CANCER; CELL DIFFERENTIATION; CELL MIGRATION; CLINICAL TRIAL; CREAM; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG APPROVAL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERANCE; DYSTROPHY; ENZYME INHIBITION; GENE TARGETING; GENETIC DISORDER; GROWTH STIMULATION; HAIR FOLLICLE; HAIR GROWTH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MALE TYPE ALOPECIA; NEUROLOGIC DISEASE; NONHUMAN; PHOTODYNAMIC THERAPY; REVIEW; SKIN MANIFESTATION;

ALOPECIA; ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HUMANS;

EID: 15544380012     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.2.177     Document Type: Review

References (47)

1. PRICE VH: Treatment of hair loss. N. Engl. J. Med. (1999) 341(13):964-973.
2. MADANI S, SHAPIRO J: Alopecia areata update. J. Am. Acad. Dermatol. (2000) 42(4):549-566.
3. MacDONALD HULL SP, WOOD ML, HUTCHINSON PE, SLADDEN M, MESSENGER AG: Guidelines for the management of alopecia areata. Br. J. Dermatol. (2003) 149(4):692-699.
4. FREYSCHMIDT-PAUL P, HOFFMANN R, LEVINE E, SUNDBERG JP, HAPPLE R, McELWEE KJ: Current and potential agents for the treatment of alopecia areata. Curr. Pharm. Des. (2001) 7(3):213-230.
5. CASH TF: The psychology of hair loss and its implications for patient care. Clin. Dermatol. (2001) 19:161-166.
6. MIRMIRANI P, PRICE VH: Androgenetic alopecia: advice and treatment continuing medical education program. Powerpak CE (2001).
7. PAUS R: Principles of hair cycle control. Clin. Dermatol. (1998) 25:793-802.
8. SUSSER WS, WHITAKER-WORTH DL, GRANT-KELS JM: Mucocutaneous reactions to chemotherapy. J. Am. Acad. Dermatol. (1999) 40 367-398.
9. BOTCHKAREV VA: Molecular mechanisms of chemotherapy-induced hair loss. J. Invest. Dermatol. (2003) 8:72-75.
10. BANDARANAYAKE I, MIRMIRANI P: Hair loss remedies-separating fact from fiction. Cutis (2004) 73(2):107-114.
11. SAWAYA ME, SHAPIRO J: Alopecia. Unapproved treatments or indications. Clin. Dermatol. (2000) 18:177-186.
12. BUHL AE: Minoxidil's action in hair follicles. J. Invest. Dermatol. (1991) 96(Suppl.):73S-74S.
13. RITTMASTER RS: Finasteride. N. Engl. J. Med. (1994) 330:120-125.
14. RIDDERHEIM M, BJURBERG M, GUSTAVSSON A: Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitised scalp-cooling system used in 74 patients. Support Care Cancer (2003) 11:371-377.
15. CHRISTODOULOU C, KLOUVAS G, EFSTATHIOU E et al.: Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia. Oncology (2002) 62:97-102.
16. DUVIC M, LEMAK NA, VALERO V et al.: A randomized trial of minoxidil in chemotherapy-induced alopecia. J. Amer. Acad. Derm. (1996) 35:74-78.
17. SOVAK M, SELIGSON AL, KUCEROVA R, BIENOVA M, HAJDUCH M, BUCEK M: Fluridil, a rationally designed topical agent for androgeneric alopecia: first clinical experience. Dermatol. Surg. (2002) 28 8):678-685.
18. SAWAYA ME: RU-58841 a new therapeutic agent affecting androgen receptor molecular interactions in human hair follicles. Hair research for the next millennium. (1996) 355-358.
19. IMAMURA K, BONFILS A, DIANI A, UNO H: The effect of topical RU58841 (androgen receptor blocker) combined with minoxidil on hair growth in macaque. J. Invest. Dermatol. (1998)110:679.
20. PAN HJ, WILDING G, UNO H et al.: Evaluation of RU-58841 as an antiandrogen in prostate pc3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques. Endocrine (1998) 9:39-43.
21. BROUWER B, TETELIN C, LEROY T, BONFILS A, VAN NESTE D: A controlled study of the effects of RU-58841, a non-steroidal antiandrgoen, on human hair production by balding scalp grafts maintained on testosterone-conditioned nude mice. Br. J. Dermatol. (1997) 137:699-702.
22. BATTMAN T, BONFILS A, BRANCHE C et al.: RU-58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism. J. Steroid Biochem. Mol. Biol. (1994) 48:55-60.
23. BALANA ME, ROGER CA, DUGOUR AV, KERNER NA: Antiandrogen oligonucleotides: active principles in hair and skin-derived culture cells. J. Drugs Dermatol. (2004) 3:287-294.
24. GARRETT R, GRISHAM C: DNA replication and repair. In: Biochemistry. Saunders College Publishing. Harcourt Brace College Publishers. (1995):948.
25. STEIN CA, The experimental use of antisense oligonucleotides: a guide for the perplexed. J. Clin. Invest. (2001) 108 641-644.
26. SHIRAI A, IKEDA J, KAWASHIMA S, TAMAOKI T, KAMIYA T: KF19418, a new compound for hair growth promotion in vitro and in vivo mouse models. J. Dermatol. Sci. (2001) 25(3):213-218.
27. NUSSBAUMER P, BILLICH A: Steroid sulfatase inhibitors. Med. Res. Rev. (2004) 24:529-576.
28. SAWAYA ME, HONIG LS, GARLAND LD, HSIA SL: Delta 5-3 β-hydroxysteroid dehydrogenase activity in sebaceous gland of scalp in male pattern baldness. J. Invest. Dermatol. (1988) 91 101-105.
29. SAWAYA ME: Steroid chemistry and hormone controls during the hair follicle cycle. Ann. NY Acad. Sci. (1991) 642:376-383.
30. HOFFMANN R, ROT A, NIIYAMA S, BILLICH A: Steroid sulfatase in the human hair follicle concentrates in the dermal papilla. J. Invest. Dermatol. (2001) 117:1342-1348.
31. HOFFMANN R, HAPPLE R: Finasteride is the main inhibitor of 5-α-reductase activity in microdissectd dermal papillae of human hair follicles. Arch. Dermatol. Res. (1999) 291:100-103.
32. RANDALL VA, THORNTON MJ, MESSENGER AG, HIBBERTS NA, LOUDON AS, BRINKLOW BR: Hormones and hair growth: variations in androgen receptor content of dermal papilla cells cultured from human and red deer (Cervus Elaphus) hair follicles. J. Invest. Dermatol. (1993) 101 114S-120S.
33. PHILP D, NGUYEN M, SCHEREMETA B et al.: Thymosin β4 increases hair growth by activation of hair follicle stem cells. FASEB J. (2004) 18:385-387.
34. PHILP D, GOLDSTEIN AL, KLEINMAN HK: Thymosin β4 promotes angiogenesis, wound healing, and hair follicle development. Mech. Ageing Dev. (2004) 125:113-115.
35. PETERS E, FOITZIK A, PAUS R, RAY S, HOLICK MF: A new strategy for modulating chemotherapy-induced alopecia, using PTH/PTHrP receptor agonist and antagonist. J. Invest. Dermatol. (2001) 117 173-178.
36. SCHILLI M, RAY S, PAUS R, OBITABOT E, HOLICK MF: Control of hair growth with parathyroid hormone (7-34). J. Invest. Dermatol. (1997) 108:928-932.
37. PAUS R, HANDJISKI B, EICHMULLER S, CZARNETZKI BM: Chemotherapy-induced alopecia in mice. Induction by cyclophosphamide, inhibition by cycloporine A, and modulation by dexamethasone. Am. J. Pathol. (1994) 114:719-734.
38. SLOMINSKI A, PAUS R, PLONKA P et al.: Pharmacological disruption of hair follicle pigmentation by cyclophosphamide as a model for studying the melanocyte response to and recovery from cytotoxic drug damage in situ. J. Invest. Dermatol. (1996) 106:1203-1211.
39. SREDNI B, CASPI RR, KLEIN A et al.: A new immunomodulating compound (AS-101) with potential therapeutic application. Nature (1987) 330(6144):173-176.
40. SREDNI B, ALBECK M, KAZIMIRSKY G, SHALIT F: The immunomodulator AS-101 administered orally as a chemoprotective and radioprotective agent. Int. J. Immunopharmacol. (1992) 14 4):613-619.
41. SREDNI B, XU RH, ALBECK M et al.: The protective role of the immunomodulator AS-101 against chemotherapy-induced alopecia studies on human and animal models. Int. J. Cancer (1996) 65 1):97-103.
42. SREDNI B, GAL R, COHEN IJ et al.: Hair growth induction by the tellurium immunomodulator AS-101: association with delayed terminal differentiation of follicular keratinocytes and ras-dependent up-regulation of KGF expression. FASEB J. (2004) 18 2):400-402.
43. SATO N, LEOPOLD PL, CRYSTAL RG: Effect of adenovirus-mediated expression of Sonic hedgehog gene on hair regrowth in mice with chemotherapy-induced alopecia. J. Natl. Cancer Inst. (2001) 93 24):1858-1864.
44. TSUDA T, OHMORI Y, MURAMATSU H et al.: Inhibitory effect of M-50054, a novel inhibitor of apoptosis, on anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia. Eur. J. Pharmacol. (2001) 433(1):37-45.
45. LI L, HOFFMAN RM: Model of selective gene therapy of hair growth: liposome targeting of the active Lac-Z gene to hair follicles of histocultured skin. In Vitro Cell Dev. Biol. Anim. (1995) 31 1):11-13.
46. DOMASHENKO A, GUPTA S, COTSARELIS G: Efficient delivery of transgenes to human hair follicle progenitor cells using topical lipoplex. Nat. Biotechnol. (2000) 18(4):420-423.
47. SAITO N, ZHAO M, LI L et al.: High efficiency genetic modification of hair follicles and growing hair shafts. Proc. Natl Acad. Sci. USA (2002) 99(20):1312-13124.